C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) A61K 31/70 (2006.01) A61K 48/00 (2006.01) C07H 21/00 (2006.01) C12N 9/12 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2132094
2132094 9319203 PCTABS00025 Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding PKC. Oligonucleotides specifically hybridizable with a translation initiation site, 5'-untranslated region or 3'- untranslated region are provided. Oligonucleotides specifically hybridizable with a particular PKC isozyme or set of isozymes are also provided. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to PKC are disclosed.
Bennett C. Frank
Dean Nicholas
Isis Pharmaceuticals Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Oligonucleotide modulation of protein kinase c does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide modulation of protein kinase c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide modulation of protein kinase c will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1857199